20.500.12556/RUL-125359 Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy In the last decade, cancer immunotherapy has emerged as an effective alternative to traditional therapies such as chemotherapy and radiation. In contrast to the latter, cancer immunotherapy has the potential to distinguish between cancer and healthy cells, and thus to avoid severe and intolerable side-effects, since the cancer cells are effectively eliminated by stimulated immune cells. The cytosolic nucleotide binding oligomerization domains 1 and 2 receptors (NOD1 and NOD2) are important components of the innate immune system and constitute interesting targets in terms of strengthening the immune response against cancer cells. Many NOD ligands have been synthesized, in particular NOD2 agonists that exhibit favorable immunostimulatory and anticancer activity. Among them, mifamurtide has already been approved in Europe by the European Medicine Agency for treating patients with osteosarcoma in combination with chemotherapy after complete surgical removal of the primary tumor. This review is focused on NOD receptors as promising targets in cancer immunotherapy as well as summarizing current knowledge of the various NOD ligands exhibiting antitumor and even antimetastatic activity in vitro and in vivo. adjuvants cancer immunotherapy immunotherapeutics NOD1 agonists NOD1 antagonists NOD2 agonists NOD2 antagonists ligandi imunoterapevtiki NOD1 agonisti NOD1 antagonisti NOD2 agonisti NOD2 antagonisti true false true Angleški jezik Slovenski jezik Članek v reviji 2021-03-12 10:49:29 2021-03-12 10:49:32 2022-09-05 03:50:21 0000-00-00 00:00:00 2019 0 0 Str. 1447-1484 iss. 5 Vol. 39 2019 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 2019-12-13 615.4:54 1098-1128 10.1002/med.21557 4641905 512824089 RAZ_Nabergoj_Sanja_2019.pdf RAZ_Nabergoj_Sanja_2019.pdf 1 E9F55F2C718B5EAC6FC1AB802D818619 36d74a60afd0790259cf99c71399eec5386aea4f206ea919a9242a3946249a74 b1f5aec8-a1bb-11eb-a523-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=141048 https://onlinelibrary.wiley.com/doi/10.1002/med.21557 1 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=141047 Fakulteta za farmacijo 0 0 0